Any current/future new fundraising through debt or equity?

For the Baba deal, Ami Organics will not be raising any significant debt; instead, they will be issuing preferential shares corresponding to the INR68 crore deal value. There will be minimal cash involvement in the Baba deal. Current year capex guidance is INR200-220 crores, including the Ankleshwar brownfield project, but no mention of new fundraising for this. Maintenance capex is INR35 crores, with additional capex planned for solar and electrolyte capacity, to be announced later. No explicit mention of any other immediate or planned fundraising through debt or equity in the discussion.

Any current/future capex/capital investment/strategic investment?

For FY 2024, capex outlay is expected between INR 200 crores to INR 220 crores, including the brownfield project at Ankleshwar. Greenfield facility capex is around INR 160-170 crores scheduled for this year. Maintenance capex (excluding electrolyte business) is about INR 35 crores. Additional capex planned for solar projects though specifics will be announced later. Electrolyte business capex is anticipated in the second half of FY 2024 once orders increase; exact amount to be announced. Total capex for the year exceeds INR 200 crores when combining greenfield and other projects. C

Future growth expectations in sales/revenue/volumes?

The company expects a 25%+ growth in specialty chemicals and 20%-22% growth in the core pharma business (Page 14). Volume growth, rather than price increases, will drive top-line growth as prices are currently suppressed (Page 16). The new Ankleshwar greenfield facility, operational by December 2023, will enable 4x volume growth compared to Unit 1 in Surat, supporting FY '24 to FY '26 growth (Pages 10, 17). Specialty chemical segment aims for 2.5x revenue growth over the next 2-3 years, with several new molecules to be commercialized in FY '24 (Pages 8-9). Electrolyte additives segment expects

Future growth expectations in earnings/operating earnings/profits/EPS?

FY'24 revenue growth expected to continue strongly, driven by advanced pharmaceutical intermediates and specialty chemicals with a 2.5x revenue growth target in 2-3 years. EBITDA margins improving quarter-on-quarter; currently at 21.9% with sustained margin improvement expected. PAT margins steady with a 15.8% YoY growth reported for FY'23; further margin expansion likely as high-value contracts mature. Specialty chemical segment aiming for 18%-19% margins this year, up from previous levels. Margin expansion is a continuous process; expected 100-150 bps improvement with better volumes

Current/ Expected Orderbook/ Pending Orders?

Several contracts for FY '25 and FY '26 are in line, including in UV absorbers and petrochemicals, with Letters of Intent (LOIs) already signed. LOIs will be disclosed once they materialize and convert into Memorandums of Understanding (MOUs) in FY '24 and '25. Specialized contracts including electrolyte additives show progressing orders, with 6 customers approved worldwide and plant-scale trial commercial orders received. Orders for VCB and FEC electrolyte products are in hand; commercialization expected this year with both domestic and international customers. Working capital improvements an

IN US

Sale is live|00:00:00left today

Acutaas Chemicals LtdQ1 FY24Pharmaceuticals & Biotechnology

Acutaas Chemicals Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹3,619P/E: 62.8Market Cap: ₹22.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

→The company expects a 25%+ growth in specialty chemicals and 20%-22% growth in the core pharma business (Page 14).
→Volume growth, rather than price increases, will drive top-line growth as prices are currently suppressed (Page 16).
→The new Ankleshwar greenfield facility, operational by December 2023, will enable 4x volume growth compared to Unit 1 in Surat, supporting FY '24 to FY '26 growth (Pages 10, 17).
→Specialty chemical segment aims for 2.5x revenue growth over the next 2-3 years, with several new molecules to be commercialized in FY '24 (Pages 8-9).
→Electrolyte additives segment expects initial revenues from H1 FY '24, with a large market opportunity ($2-$3 billion industry) and capacity expansion planned as orders increase (Pages 4,13,17).
→Baba Fine Chemicals acquisition anticipates 3-4x growth in revenue in the near term due to new product launches and expanded global market reach (Page 13).

Margin guidance

Category 2

→FY'24 revenue growth expected to continue strongly, driven by advanced pharmaceutical intermediates and specialty chemicals with a 2.5x revenue growth target in 2-3 years.
→EBITDA margins improving quarter-on-quarter; currently at 21.9% with sustained margin improvement expected.
→PAT margins steady with a 15.8% YoY growth reported for FY'23; further margin expansion likely as high-value contracts mature.
→Specialty chemical segment aiming for 18%-19% margins this year, up from previous levels.
→Margin expansion is a continuous process; expected 100-150 bps improvement with better volumes and operational efficiencies over FY'24 and FY'25.
→New product introductions and long-term contracts (e.g., Fermion) will drive revenue visibility and margin improvement.
→Capex for growth (including electrolyte segment) suggests scaling up operations, supporting volume and profitability growth.
→Conservative guidance on margin reductions due to new product capacity investments, but overall profitability is expected to improve as volumes grow.

3 more insights locked — sign up free to unlock

Fundraise plans

→For the Baba deal, Ami Organics will not be raising any significant debt; instead, they will be issuing preferential shares corresponding to the INR68 crore deal value.
→There will be minimal cash involvement in the Baba deal.
→Current year capex guidance is INR200-220 crores, including the Ankleshwar brownfield project, but no mention of new fundraising for this.
→Maintenance capex is INR35 crores, with additional capex planned for solar and electrolyte capacity, to be announced later.
→No explicit mention of any other immediate or planned fundraising through debt or equity in the discussion.

Order book

→Several contracts for FY '25 and FY '26 are in line, including in UV absorbers and petrochemicals, with Letters of Intent (LOIs) already signed.
→LOIs will be disclosed once they materialize and convert into Memorandums of Understanding (MOUs) in FY '24 and '25.
→Specialized contracts including electrolyte additives show progressing orders, with 6 customers approved worldwide and plant-scale trial commercial orders received.
→Orders for VCB and FEC electrolyte products are in hand; commercialization expected this year with both domestic and international customers.
→Working capital improvements and growing order book support sustained growth.
→No specific exact current total order book value mentioned, but positive outlook on conversion of LOIs to firm orders and expected volume growth across segments.

Capex plans

Yes

→For FY 2024, capex outlay is expected between INR 200 crores to INR 220 crores, including the brownfield project at Ankleshwar.
→Greenfield facility capex is around INR 160-170 crores scheduled for this year.
→Maintenance capex (excluding electrolyte business) is about INR 35 crores.
→Additional capex planned for solar projects though specifics will be announced later.
→Electrolyte business capex is anticipated in the second half of FY 2024 once orders increase; exact amount to be announced.
→Total capex for the year exceeds INR 200 crores when combining greenfield and other projects.
→Capacity expansions ongoing at Unit 3 (Jaghadia) to increase specialty chemicals production by about 15-20%.
→Future capex plans depend on order inflows, especially from electrolyte and solar segments.

How does Acutaas Chemicals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Acutaas Chemicals Ltd

Rev 2Mar 2

See full Pharmaceuticals & Biotechnology sector rankings